Arbutus Biopharma Corp (ABUS)
3.92
+0.06
(+1.55%)
USD |
NASDAQ |
Nov 05, 14:38
Arbutus Biopharma Price to Book Value: 6.043 for Nov. 5, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 5.951 |
| November 01, 2024 | 6.105 |
| October 31, 2024 | 5.928 |
| October 30, 2024 | 6.074 |
| October 29, 2024 | 6.228 |
| October 28, 2024 | 6.244 |
| October 25, 2024 | 6.120 |
| October 24, 2024 | 6.244 |
| October 23, 2024 | 6.259 |
| October 22, 2024 | 6.213 |
| October 21, 2024 | 6.274 |
| October 18, 2024 | 6.398 |
| October 17, 2024 | 6.352 |
| October 16, 2024 | 6.475 |
| October 15, 2024 | 6.336 |
| October 14, 2024 | 5.951 |
| October 11, 2024 | 5.982 |
| October 10, 2024 | 5.843 |
| October 09, 2024 | 5.797 |
| October 08, 2024 | 5.812 |
| October 07, 2024 | 5.750 |
| October 04, 2024 | 5.92 |
| October 03, 2024 | 5.935 |
| October 02, 2024 | 6.012 |
| October 01, 2024 | 5.904 |
| Date | Value |
|---|---|
| September 30, 2024 | 5.935 |
| September 27, 2024 | 5.904 |
| September 26, 2024 | 6.105 |
| September 25, 2024 | 6.028 |
| September 24, 2024 | 6.198 |
| September 23, 2024 | 6.228 |
| September 20, 2024 | 6.198 |
| September 19, 2024 | 6.382 |
| September 18, 2024 | 6.367 |
| September 17, 2024 | 6.29 |
| September 16, 2024 | 6.568 |
| September 13, 2024 | 6.891 |
| September 12, 2024 | 6.644 |
| September 11, 2024 | 7.03 |
| September 10, 2024 | 7.03 |
| September 09, 2024 | 6.922 |
| September 06, 2024 | 7.014 |
| September 05, 2024 | 6.953 |
| September 04, 2024 | 6.305 |
| September 03, 2024 | 6.151 |
| August 30, 2024 | 5.966 |
| August 29, 2024 | 5.904 |
| August 28, 2024 | 5.935 |
| August 27, 2024 | 5.966 |
| August 26, 2024 | 5.966 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.776
Minimum
May 10 2022
7.03
Maximum
Sep 10 2024
3.421
Average
2.881
Median
Nov 30 2023
Price to Book Value Benchmarks
| Biomarin Pharmaceutical Inc | 2.315 |
| GlycoMimetics Inc | 1.250 |
| FibroGen Inc | -- |
| Cidara Therapeutics Inc | 0.7176 |
| Cue Biopharma Inc | 4.734 |
Price to Book Value Related Metrics
| PS Ratio | 68.16 |
| Price | 3.92 |
| Earnings Yield | -11.48% |
| Market Cap | 740.03M |